Published in Endocrinology on August 07, 2003
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev (2010) 1.92
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol (2004) 1.82
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist (2010) 1.37
The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila) (2010) 1.28
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res (2006) 1.09
Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res (2007) 1.03
Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res (2009) 1.00
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res (2011) 0.92
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res (2009) 0.89
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag (2013) 0.87
New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res (2004) 0.86
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res (2008) 0.85
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag Res (2010) 0.85
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. Int J Cancer (2015) 0.82
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. Transl Oncol (2011) 0.82
Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) (2012) 0.81
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer (2010) 0.80
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Omics and therapy - a basis for precision medicine. Mol Oncol (2012) 0.79
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review. J Cancer (2015) 0.76
Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res (2016) 0.76
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer (2016) 0.75
Femara and the future: tailoring treatment and combination therapies with Femara. Breast Cancer Res Treat (2007) 0.75
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors. Breast Cancer Res (2009) 0.75
Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. Oncotarget (2016) 0.75
Localization of single copy DNA sequences of G-banded human chromosomes by in situ hybridization. Chromosoma (1981) 9.30
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A (1986) 8.06
HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science (1985) 7.70
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med (1998) 6.86
Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature (1997) 6.73
A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell (2000) 5.31
Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med (2001) 4.19
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med (1995) 3.88
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. Nature (1983) 3.77
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J (1993) 3.75
Localization of the human insulin gene to the distal end of the short arm of chromosome 11. Proc Natl Acad Sci U S A (1981) 3.17
An iron-regulated ferric reductase associated with the absorption of dietary iron. Science (2001) 2.90
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA (1986) 2.30
Targeted disruption of the beta 3-adrenergic receptor gene. J Biol Chem (1995) 2.27
Occurrence of a transposition from the X-chromosome long arm to the Y-chromosome short arm during human evolution. Nature (1984) 2.21
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain (1991) 2.15
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature (1985) 1.96
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer (2004) 1.91
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol (1986) 1.88
Lack of obesity and normal response to fasting and thyroid hormone in mice lacking uncoupling protein-3. J Biol Chem (2000) 1.86
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet (2010) 1.83
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Chromosomal mapping of the mink cell focus-inducing and xenotropic env gene family in the mouse. Proc Natl Acad Sci U S A (1983) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology (2001) 1.62
Chromosomal localization of the human placental lactogen-growth hormone gene cluster to 17q22-24. Am J Hum Genet (1982) 1.57
Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J Biol Chem (1997) 1.53
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 1.53
Restriction of energy intake, energy expenditure, and aging. Free Radic Biol Med (2000) 1.51
Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett (2005) 1.50
Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology (2011) 1.49
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat (2005) 1.41
Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat. Eur J Pharmacol (1990) 1.41
Changes in haemodynamic parameters following Tai Chi Chuan and aerobic exercise in patients recovering from acute myocardial infarction. Postgrad Med J (1996) 1.40
Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med (2009) 1.40
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol (1986) 1.39
Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer (1981) 1.38
XIX. Report of a Case of Large Renal Calculus. Ann Surg (1908) 1.38
Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp Biol Med (Maywood) (2001) 1.36
Effects of genetic background on thermoregulation and fatty acid-induced uncoupling of mitochondria in UCP1-deficient mice. J Biol Chem (2001) 1.33
Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol (2003) 1.33
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem (1981) 1.31
Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res (1988) 1.31
Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer (1986) 1.30
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther (1999) 1.28
Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat (1994) 1.27
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25
Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer (1994) 1.25
Microfabricated silicon microneedles for nonviral cutaneous gene delivery. Br J Dermatol (2004) 1.25
Mitochondrial uncoupling proteins in energy expenditure. Annu Rev Nutr (2000) 1.24
Pharmacological inhibition of infectivity of HTLV-III in vitro. Cancer Res (1985) 1.24
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer (1986) 1.24
Control of the effective P/O ratio of oxidative phosphorylation in liver mitochondria and hepatocytes. Biochem J (1993) 1.24
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer (1987) 1.23
The binding of tamoxifen to oestrogen receptor proteins under equilibrium and non-equilibrium conditions. Eur J Cancer (1979) 1.23
Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab (1988) 1.22